Tandem folding methods to improve protein folding yield

US10633414B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10633414-B2
Application numberUS-201615748012-A
CountryUS
Kind codeB2
Filing dateJul 27, 2016
Priority dateJul 27, 2015
Publication dateApr 28, 2020
Grant dateApr 28, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Methods of refolding proteins are provided, especially cysteine-containing proteins such as insulin, proinsulin, and analogues thereof. The methods make used of tandem folding via the addition, at two different time, of two different reducing agents. A first reversible reducing agent can be added to induce folding and, at a later time, a second irreversible reducing agent can be added to prevent and/or reverse the formation of aggregates via intermolecular sulfide bonds. The methods can be used to reform a variety of cysteine-containing proteins with high yield of the native form, e.g. about 60 mol %, 70 mol %, or more.

First claim

Opening claim text (preview).

We claim: 1. A method of refolding a solubilized cysteine-containing protein to its native form, the method comprising adding a reversible reducing agent to a solution containing the solubilized cysteine-containing protein to initiate folding of the cysteine-containing protein, wherein the reversible reducing agent is added at a ratio of [reversible reducing agent]:[thiols in the cysteine-containing protein] of 3:1 to 4:1; and adding an irreversible reducing agent to the solution at a time after the initiation of folding to breakdown aggregates of the cysteine-containing protein. 2. The method of claim 1 , wherein the time after the initiation of folding is when the concentration of the dimer in the solution is 5 mol % to 12 mol % based upon the concentration of the cysteine-containing protein. 3. The method of claim 1 , wherein the time after the initiation of folding is when the concentration of the dimer in the solution is 1.5 to 3.0 times the concentration of the dimer in the solution prior to the addition of the reversible reducing agent. 4. The method of claim 1 , wherein the time after the initiation of folding is 5 minutes to 15 minutes. 5. The method of claim 1 , wherein the irreversible reducing agent has a redox potential of −0.3 V to −0.35 V at a pH above 7.0, and wherein the irreversible reducing agent has a redox equilibrium constant of 10 3 to 10 5 . 6. The method of claim 1 , wherein the irreversible reducing agent is added at a ratio of [irreversible reducing agent]:[thiols in the cysteine-containing protein] of 0.5:1 to 0.8:1. 7. The method of claim 1 , wherein the cysteine-containing protein is a recombinant protein selected from the group consisting of an enzyme, an antibody, an antigen, a hormones, and a cytokine. 8. The method of claim 7 , wherein the recombinant protein is an inclusion body isolated from an Escherichia coli expression system. 9. The method of of claim 1 , wherein the cysteine-containing proteins is insulin, an insulin analogue, or a proinsulin. 10. The method of claim 1 , wherein the concentration of the cysteine-containing protein in the solution prior to addition of the reversible reducing agent is 0.3 g/L to 1 g/L. 11. The method of claim 1 , further comprising dissolution of the cysteine-containing protein at an alkaline pH to form the solubilized cysteine-containing protein. 12. The method of claim 11 , where the alkalinepH is 11.5-12.5. 13. The method of claim 11 , where the temperature is 4° C. to 8° C. 14. The method of claim 1 , wherein the pH of the solution after the addition of the reversible reducing agent is 10.75 to 10.85. 15. The method of claim 1 , wherein the reversible reducing agent is cysteine-HCl dissolved to a 200 mM to 900 mM at 4° C. to 8° C. and acidic pH.

Assignees

Inventors

Classifications

  • Extraction; Separation; Purification · CPC title

  • Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title

  • C07K1/1133Primary

    by redox-reactions involving cystein/cystin side chains · CPC title

  • Chemistry & Metallurgy · mapped topic

  • Escherichia coli · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10633414B2 cover?
Methods of refolding proteins are provided, especially cysteine-containing proteins such as insulin, proinsulin, and analogues thereof. The methods make used of tandem folding via the addition, at two different time, of two different reducing agents. A first reversible reducing agent can be added to induce folding and, at a later time, a second irreversible reducing agent can be added to preven…
Who is the assignee on this patent?
Purdue Research Foundation
What technology area does this patent fall under?
Primary CPC classification C07K1/1133. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).